Company intelligence

TPST

Tempest Therapeutics, Inc. · NASDAQ · Healthcare

Price$0.78-3.38% · −$0.03

Market cap12.53MEquity value

P / E-0.2Trailing ratio

Volume138.56KLatest session

Market data

TPST price chart

TradingView

Related signals

1 min delayed

Browse public TPST signals with their source context and measured market impact. Open any signal for its permanent analysis page.

TPSTOct 10, 2024-28.63% since signal

Why Is Cancer Focused Tempest Therapeutics Stock Trading Higher On Thursday?

TPST shares rose 23% on news of Roche collaboration. Tempest is advancing amezalpat into a pivotal Phase 3 liver cancer trial. Roche will supply atezolizumab, enhancing treatment options for HCC. Positive Phase 2 results showed significant survival improvements. Phase 3 study is expected to begin in Q1 2025.

View signal analysis

Research